We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CytomX Announces Third Target Selection by BMS
News

CytomX Announces Third Target Selection by BMS

CytomX Announces Third Target Selection by BMS
News

CytomX Announces Third Target Selection by BMS

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CytomX Announces Third Target Selection by BMS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, has announced the selection of a third target by Bristol-Myers Squibb in accordance with the companies’ strategic oncology collaboration established in May 2014, triggering a $10 million milestone payment.

“Our collaboration with Bristol-Myers Squibb has progressed very well and we are pleased to expand our collaborative work to a third target,” said Sean McCarthy, D.Phil., President and Chief Executive Officer of CytomX. “We look forward to continuing to work closely with the BMS team to advance product candidates into development.”

Investigational therapeutics developed with CytomX's Probody platform are designed to be active in the tumor while sparing healthy tissue. By restricting activity to the tumor microenvironment, investigational Probody therapeutics directed against both validated and novel targets have been shown preclinically to enable anti-tumor efficacy with an enhanced safety window, relative to traditional antibody-based therapies.

Advertisement